Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

Inclusion Criteria: * Histological or cytological proof of epithelial ovarian cancer, and proven p53 mutated pathway by PCR/Sequencing. IHC will also be performed. In the additional safety and efficacy cohort also inclusion of NSCLC, SCLC, cervical and endometrial cancer (only ovarian cancer cohort is pursued) * Measurable disease on a CT-scan or elevated Cancer Antigen (CA)-125 levels that can be monitored. * Patients previously received standard 1st line platinum therapy (combined with paclitaxel) for epithelial ovarian cancer, and showed recurrence on or within 3 months of this treatment (relapse within 6 months in the additional safety and efficacy cohort) * Able and willing to voluntarily give written informed consent. * Able and willing to undergo blood sampling for pharmacokinetics and pharmacodynamics. * Life expectancy ≥ 3 months allowing adequate follow up of toxicity evaluation and anti-tumor activity. * Minimal acceptable safety laboratory values: * Absolute neutrophil count (ANC) of ≥ 1.5 x 109 /L (or 1500/m3). * Platelet count of ≥ 100 x 109 /L (or 100,000/mm3). * Hemoglobin ≥ 5.6 mmol/L (or 9.1 g/dl). * Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ALAT and ASAT ≤ 2.5 x ULN, or ALAT and ASAT ≥ 5x ULN in case of liver metastases. * Renal function as defined by serum creatinine ≥ 1.5 x ULN or creatinine clearance ≥ 60 ml/min for patients with creatinine levels ≥ 1.5 x ULN (by Cockcroft-Gault formula). * WHO performance status of ≤ 2 on t…